Cargando…
High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population
BACKGROUND: Pathogenic BRCA1 founder mutations (c.4035delA, c.5266dupC) contribute to 3.77% of all consecutive primary breast cancers and 9.9% of all consecutive primary ovarian cancers. Identifying germline pathogenic gene variants in patients with primary breast and ovarian cancer could significan...
Autores principales: | Maksimenko, J., Irmejs, A., Trofimovičs, G., Bērziņa, D., Skuja, E., Purkalne, G., Miklaševičs, E., Gardovskis, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989401/ https://www.ncbi.nlm.nih.gov/pubmed/29928469 http://dx.doi.org/10.1186/s13053-018-0094-0 |
Ejemplares similares
-
Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
por: Sæther, Nikolai Havn, et al.
Publicado: (2018) -
Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers
por: Līcīte, Baiba, et al.
Publicado: (2021) -
BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012) -
Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014) -
A novel frequent BRCA1 recurrent variant c.5117G > A (p.Gly1206Glu) identified after 20 years of BRCA1/2 research in the Baltic region: cohort study and literature review
por: Loza, P., et al.
Publicado: (2021)